-+ 0.00%
-+ 0.00%
-+ 0.00%

Takeda's FRUZAQLA Approved For Reimbursement By BC Cancer For Metastatic Colorectal Cancer

Benzinga·12/16/2025 13:17:30
Listen to the news

Takeda Canada Inc. ("Takeda") is pleased to announce that FRUZAQLATM (fruquintinib capsules) will now be reimbursed by BC Cancer as a treatment option for adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with, or are not considered candidates, for available standard therapies.[1]  This treatment is available to patients under certain criteria.